COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

CPTAC Establishes Formal Relationships with Two Academic Institutions in Taiwan

The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) has entered into memorandum of understandings (MOUs) with Chang Gung University and Academia Sinica, in Taipei, Taiwan.

These organizations agree to develop international cooperation on using proteomic methods to characterize tumors and compare findings to other diagnostic features including genomic characterization. The motivation for these MOUs is to gain a deeper understanding of cancer at the molecular level, identify targets and pathways of therapeutic intervention, share knowledge and experience in support each other's endeavors in proteogenomics science, and promote the development and adoption of standards in basic and clinical medicine.